Zenotech Laboratories Reports Q3 FY24-25 Results, Highlights Mixed Financial Trends

Zenotech Laboratories, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The company has experienced a stable financial performance during Q3 FY24-25, with notable developments in its evaluation. The net sales for the quarter reached Rs 11.24 crore, marking the highest figure in the last five quarters, indicating a positive near-term sales trend. Additionally, the Profit Before Tax (PBT) stood at Rs 2.12 crore, reflecting a growth of 22.4% compared to the average PBT of the previous four quarters, which was Rs 1.73 crore. This suggests a favorable near-term outlook for PBT. Conversely, the Profit After Tax (PAT) for the half-year period was recorded at Rs 1.93 crore, showing a significant decline of 68.86% year on year. This aspect highlights a challenging trend for PAT in the near term. Overall, Zenotech Laboratories has undergone an adjustment in its evaluation, with the score shifting to -4 from -15 over the past three months. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.